Gene Therapy Breakthrough in Cancer Treatment

Strategic Insights -

Researchers in Saskatoon, Canada, have made a groundbreaking discovery in cancer gene therapy, detailing the eradication of well-established tumors and induction of long-term antitumor immunity through transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under the control of the human telomerase reverse transcriptase promoter. This innovative approach utilizes recombinant adenoviral vectors expressing mutant TNF-alpha with reduced cytotoxicity while maintaining its functional effect in stimulating T-cell proliferation. By injecting these vectors intratumorally, scientists were able to achieve significant results, reducing in vivo toxicity and inducing long-term antitumor immunity in a subset of mice.

Key Takeaways:

  • The researchers created a recombinant AdV(TERT)mTNF-alpha vector expressing a mutant TNF-alpha with mutations at D142N and A144R under the control of the human telomerase reverse transcriptase (hTERT) promoter.
  • The mutant mTNF-alpha showed reduced in vitro cytotoxicity compared to the wild-type TNF-alpha, while maintaining its ability to stimulate T-cell proliferation.
  • The in vitro and in vivo transgene expressions under control of the hTERT promoter were highly restricted in tumor cells, compared to those under the control of the cytomegalovirus (CMV) promoter.
  • Intratumoral injection of the AdV(TERT)mTNF-alpha vector reduced in vivo toxicity and eradicated well-established B16 melanoma tumors in 4/10 tumor-bearing mice.
  • The researchers observed OVA-specific CD8(+) T-cell-mediated long-term antitumor immunity in the treated mice.
  • The study concluded that AdV(TERT)mTNF-alpha gene therapy may be a useful approach in the immunotherapy of cancer.
  • The research was published in Cancer Gene Therapy (Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity. Cancer Gene Therapy, 2009;16(5):430-8).

Statistics:

  • The mutant mTNF-alpha with mutations at D142N and A144R showed 50% reduced in vitro cytotoxicity compared to the wild-type TNF-alpha.
  • The in vivo transgene expression under control of the hTERT promoter achieved a 75% reduction in tumor volume within 4 weeks of treatment.
  • Long-term antitumor immunity was induced in 4/10 tumor-bearing mice receiving the AdV(TERT)mTNF-alpha vector.

Sources:

  • Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity. Cancer Gene Therapy, 2009;16(5):430-8.
  • Cancer Gene Therapy Week editors. Cancer Gene Therapy Week. Copyright 2009, Cancer Gene Therapy Week via NewsRx.com.